The Development of Ru(II)-Based Photoactivated Chemotherapy Agents

Chen, Yong‐Jie; Bai, Lijuan; Zhang, Pu; Zhao, Hua; Zhou, Qianxiong

doi:10.3390/molecules26185679

Cited by 34 publications

(21 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many Ru(II) complexes can undergo photoinduced ligand dissociation, demonstrating the potential as photoactivators [287][288][289][290][291] . The mechanism of action 292 (Figure 27) is that the ruthenium complexes reach 1 MLCT state and then 3 MLCT state from the ground state under light irradiation, and the 3 MLCT excited state can enter 3 MC state (state of mind or ligand field in metal) by thermal activation. 3 MC state can lead to ligand dissociation and produce Ru (II) hydrolysate which can bind DNA, exerting cytotoxic effect.…”

Section: Photoactivated Chemotherapy (Pact)mentioning

confidence: 99%

“…3 MC state can lead to ligand dissociation and produce Ru (II) hydrolysate which can bind DNA, exerting cytotoxic effect. Currently, twophoton absorption is also used for photoactivation of ruthenium complexes 292,293 . As for the application of Ru complexes in photoactivated chemotherapy, Qianxiong Zhou et al 292 discussed the development of Ru(II) based photoactivated chemotherapy drugs, which is not discussed in detail here.…”

Section: Photoactivated Chemotherapy (Pact)mentioning

confidence: 99%

See 1 more Smart Citation

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Zhu

et al. 2022

Nanoscale

View full text Add to dashboard Cite

show abstract

Section: Photoactivated Chemotherapy (Pact)mentioning

confidence: 99%

Section: Photoactivated Chemotherapy (Pact)mentioning

confidence: 99%

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Zhu

et al. 2022

Nanoscale

View full text Add to dashboard Cite

show abstract

“…These properties have been used by several researchers to synthesize PACT drugs based in Ru-ppy complexes (10,11). The possibility of 1 O 2 generation can make some of the same complexes active in photodynamic therapy (PDT).…”

Section: Commentarymentioning

confidence: 99%

Shine, Shine, Ruthenium Caged Drug^†

Etchenique

Filevich

2022

Photochem & Photobiology

View full text Add to dashboard Cite

This is a highlight on the paper by Bonnet et al.: A Lockand-Kill Anticancer Photoactivated Chemotherapy Agent. which constitutes an important step toward establishing photoactivated chemotherapy (PACT) as a widespread tool to treat different health issues, specially tumors. PACT can be a useful technique to deliver already tested drugs, where the effect of the desired molecule is directed only to its target after light irradiation, even in the cases in which it is difficult to achieve a precise delivery in the desired organ or tissue. Ruthenium-polipyridyl caged-compounds are near ideal devices to deliver a drug in that precise fashion, albeit they usually fail in revealing their actual location due to their weak light emission properties. The mentioned work introduces a simple and clever idea: the use of a covalently linked fluorophore to map the caged-compounds in-vivo distribution prior to the eventual irradiation to activate the chemotherapy.

show abstract

“…Light-activated ruthenium complexes show great promise in their ability to target cancer cells [ 1 ] via singlet oxygen generation in photodynamic therapy (PDT) [ 2 , 3 , 4 ] or via generation of toxic species via photoactivated chemotherapy (PACT) [ 5 , 6 , 7 , 8 , 9 ]. This paper focuses primarily on PDT and correlating singlet oxygen production with other photophysical properties, including photoluminescence quantum yield and the photoluminescence lifetime.…”

Section: Introductionmentioning

confidence: 99%

Ruthenium Complexes with Protic Ligands: Influence of the Position of OH Groups and π Expansion on Luminescence and Photocytotoxicity

Oladipupo

Prescott

Blevins

et al. 2023

IJMS

View full text Add to dashboard Cite

Protic ruthenium complexes using the dihydroxybipyridine (dhbp) ligand combined with a spectator ligand (N,N = bpy, phen, dop, Bphen) have been studied for their potential activity vs. cancer cells and their photophysical luminescent properties. These complexes vary in the extent of π expansion and the use of proximal (6,6′-dhbp) or distal (4,4′-dhbp) hydroxy groups. Eight complexes are studied herein as the acidic (OH bearing) form, [(N,N)2Ru(n,n′-dhbp)]Cl2, or as the doubly deprotonated (O− bearing) form. Thus, the presence of these two protonation states gives 16 complexes that have been isolated and studied. Complex 7A, [(dop)2Ru(4,4′-dhbp)]Cl2, has been recently synthesized and characterized spectroscopically and by X-ray crystallography. The deprotonated forms of three complexes are also reported herein for the first time. The other complexes studied have been synthesized previously. Three complexes are light-activated and exhibit photocytotoxicity. The log(Do/w) values of the complexes are used herein to correlate photocytotoxicity with improved cellular uptake. For Ru complexes 1–4 bearing the 6,6′-dhbp ligand, photoluminescence studies (all in deaerated acetonitrile) have revealed that steric strain leads to photodissociation which tends to reduce photoluminescent lifetimes and quantum yields in both protonation states. For Ru complexes 5–8 bearing the 4,4′-dhbp ligand, the deprotonated Ru complexes (5B–8B) have low photoluminescent lifetimes and quantum yields due to quenching that is proposed to involve the 3LLCT excited state and charge transfer from the [O2-bpy]2− ligand to the N,N spectator ligand. The protonated OH bearing 4,4′-dhbp Ru complexes (5A–8A) have long luminescence lifetimes which increase with increasing π expansion on the N,N spectator ligand. The Bphen complex, 8A, has the longest lifetime of the series at 3.45 μs and a photoluminescence quantum yield of 18.7%. This Ru complex also exhibits the best photocytotoxicity of the series. A long luminescence lifetime is correlated with greater singlet oxygen quantum yields because the triplet excited state is presumably long-lived enough to interact with 3O2 to yield 1O2.

show abstract

The Development of Ru(II)-Based Photoactivated Chemotherapy Agents

Cited by 34 publications

References 135 publications

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Shine, Shine, Ruthenium Caged Drug^†

Ruthenium Complexes with Protic Ligands: Influence of the Position of OH Groups and π Expansion on Luminescence and Photocytotoxicity

Contact Info

Product

Resources

About

The Development of Ru(II)-Based Photoactivated Chemotherapy Agents

Cited by 34 publications

References 135 publications

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Shine, Shine, Ruthenium Caged Drug†

Ruthenium Complexes with Protic Ligands: Influence of the Position of OH Groups and π Expansion on Luminescence and Photocytotoxicity

Contact Info

Product

Resources

About

Shine, Shine, Ruthenium Caged Drug^†